Menopausal Hot Flashes Global Market Report 2024

The menopausal hot flashes market size has grown strongly in recent years. It will grow from $14.06 billion in 2023 to $14.99 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The growth observed in the historical period in the treatment of menopausal hot flashes can be attributed to several factors. These include the adoption of hormone replacement therapy as a common treatment approach, the limited availability of treatment options, increased awareness and education regarding menopausal symptoms, a shift in lifestyle management practices, and the growing interest in alternative therapies. These factors collectively contributed to the development and utilization of various strategies for managing menopausal hot flashes during the specified historical timeframe.

The menopausal hot flashes market size is expected to see strong growth in the next few years. It will grow to $18.75 billion in 2028 at a compound annual growth rate (CAGR) of 5.8%. The anticipated growth in the forecast period for the treatment of menopausal hot flashes can be attributed to several factors. These include advancements in non-hormonal therapies, a focus on individualized treatment approaches catering to specific needs, an emphasis on natural remedies, and ongoing research on neurotransmitter pathways associated with hot flashes. Key trends expected during this period encompass the adoption of non-pharmacological interventions, the integration of digital health solutions for better management, the development of novel drug formulations, the application of precision medicine in addressing menopausal symptoms, and the exploration of combination therapies. These trends collectively reflect an evolving landscape in the treatment of menopausal hot flashes, marked by innovation and a personalized approach to women's health.

The government's initiatives for women's health in menopause are expected to propel the growth of the menopausal hot flashes market going forward. The government's menopausal health initiatives include financing for novel studies to understand the menopausal transition and avoid illness and support for investigations of linked pharmacological, clinical, and epidemiological aspects and preventive research. Government initiatives for women's health frequently cover a wide variety of concerns, such as menopause health and the management of symptoms such as hot flashes, as well as efforts to promote health through risk factor research, prevention, and early diagnosis of significant health conditions. For instance, in January 2023, according to the Government of New South Wales, an Australia-based government agency, the government initiated $40.3 million over four years (2022-2023 to 2025-2026) to build up to 16 new programs for women facing severe menopausal symptoms. Therefore, the government's initiatives for women's health in menopause are driving the growth of the menopausal hot flashes market.

The increasing healthcare expenditure is expected to propel the growth of the menopausal hot flashes market going forward. Healthcare expenditure refers to the total amount of money spent on healthcare goods and services within a specific period, typically on a national or regional level. Investing in healthcare can lead to advanced treatment options, increase awareness about menopausal symptoms, support research initiatives, improve access to healthcare services, and patient support programs, research alternative therapies, and contribute to improvements in the quality of life for women experiencing menopausal hot flashes by providing access to more effective treatments and supportive care services. For instance, in May 2023, the UK's Office for National Statistics, a government agency, healthcare spending in the UK increased by 9.4% nominally and 9.7% practically. The total cost of healthcare in the UK in 2021 was $367.25 billion (£280.7 billion), pharmaceutical costs were $51.84 billion (£39.6 billion), and spending on preventative care increased to $45.93 billion (£35.1 billion). Therefore, the increasing healthcare expenditure is driving the growth of the menopausal hot flashes market.

The menopausal hot flashes market witnesses a rising inclination towards product innovations, constituting a significant trend. Notably, prominent entities within this market are actively introducing inventive solutions to fortify their market standing. An instance of this was observed in May 2023 when Astellas Pharma US Inc., a US-based pharmaceutical establishment, announced the FDA's approval of Veozah. This novel treatment, designed for menopause-induced hot flashes, marks the pioneering approval of a neurokinin 3 (NK3) receptor inhibitor for managing mild to severe hot flashes related to menopause. Its mechanism involves binding to and activating the NK3 receptor, integral in regulating body temperature within the brain.

Major industry players are strategically forging alliances to drive new product development initiatives and bolster their market presence. Such collaborations and partnerships in this domain serve to stimulate innovation, harness synergistic expertise, and expedite the progression and commercial launch of advanced therapies. For instance, in July 2022, Lisa Health Inc., a US-based digital health entity, entered a collaborative venture with Mayo Clinic, a US-based academic medical institution, to introduce 'Midday.' This app-based innovation caters to personalized menopausal management through the integration of digital therapeutics and artificial intelligence (AI). By leveraging intricate algorithms and sensor technology customized to individual stages and symptoms, Midday endeavors to address gaps in care, offering tailored guidance, educational resources, and strategies. Additionally, Midday provides users access to Mayo Clinic's technology platform, facilitating education on menopausal hormone treatment and aiding users in making informed decisions regarding its suitability.

In October 2022, Unified Women's Healthcare, a prominent US-based healthcare company specializing in women's healthcare treatment, successfully acquired Gennev for an undisclosed amount. Through this strategic acquisition, Unified Women's Healthcare aims to broaden its women's healthcare portfolio, with the objective of enhancing outcomes and the overall patient experience at every stage of a woman's healthcare journey. Gennev, the acquired company, is based in the United States and provides feminine care services, offering various treatments to empower women to take control of their health throughout and after the menopausal transition.

Major companies operating in the menopausal hot flashes market report are Pfizer Inc., Johnson & Johnson, The Procter & Gamble Company, Merck & Co. Inc., Bayer AG, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Shionogi & Co. Ltd., Gedeon Richter Plc, Lupin Limited, Hisamitsu Pharmaceutical Co. Inc., Noven Pharmaceuticals Inc., Ligand Pharmaceuticals Inc., Mithra Pharmaceuticals SA, TherapeuticsMD Inc., Theramex Ltd., Ascend Therapeutics Inc., EndoCeutics Inc., Sermonix Pharmaceuticals LLC, Ralington pharma LLP, Bionovo Inc.

North America was the largest region in the Menopausal Hot Flashes market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the menopausal hot flashes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the menopausal hot flashes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The main types of treatment for menopausal hot flashes encompass hormonal treatment, non-hormonal treatment, and alternative treatment. Hormonal treatment involves therapy for women during the menopausal period when the body ceases to produce estrogen. This therapy typically includes the administration of medications containing female hormones to replace the declining estrogen levels. Pipeline analysis in this context involves the examination of drugs in different phases of development, including phase III drugs and phase I and II drugs. These treatments are typically made available through various distribution channels, such as retail pharmacies, online pharmacies, and hospital pharmacies. The applications of these treatments can be tailored to different age groups, including 51-55-year-old women, 46-50-year-old women, and 40-45-year-old women, depending on individual needs and circumstances.

The menopausal hot flashes market research report is one of a series of new reports that provides menopausal hot flashes market statistics, including menopausal hot flashes industry global market size, regional shares, competitors with menopausal hot flashes market share, detailed menopausal hot flashes market segments, market trends, and opportunities, and any further data you may need to thrive in the menopausal hot flashes industry. This menopausal hot flashes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The menopausal hot flashes market consists of revenues earned by entities by providing estrogen therapy, and menopause hormone therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The menopausal hot flashes market also includes sales of venlafaxine, paroxetine, and escitalopram. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.